Tigecycline, an antibiotic targeting mitochondrial ribosomes, was used in combination with the BCR-ABL tyrosine kinase inhibitor imatinib and was found to be effective against CML LSCs in vitro as well as in an in vivo animal model [103]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.